Activin signalling inhibitor
Sotatercept
Brand names: Winrevair
Adult dose
Dose: Initial 0.3 mg/kg SC every 3 weeks, target 0.7 mg/kg every 3 weeks
Route: SC
Frequency: q3w
Clinical pearls
- Pulmonary arterial hypertension (WHO Group 1) as adjunct to background therapy
- Specialist PH centre
Contraindications
- Severe thrombocytopenia
- Pregnancy
- Hypersensitivity
Side effects
- Epistaxis
- Telangiectasia
- Headache
- Increased haemoglobin
- Thrombocytopenia
- Bleeding
Monitoring
- Hb
- Platelets
- BP
- 6MWT
Reference: BNF; NICE; SmPC; https://bnf.nice.org.uk/drugs/sotatercept/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024